JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2015, Vol. 53 ›› Issue (11): 37-40.doi: 10.6040/j.issn.1671-7554.0.2015.147

• Clinical Medicine • Previous Articles     Next Articles

Efficacy and safety of dabigatran etexilate versus warfarin in antithrombotic therapy for nonvalvular atrial filbrillation

LÜ Yanhong, GAO Haiqing, QIU Jie   

  1. 1. Department of Geratology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    2. Shandong Key Laboratory of Cardiovascular Proteomics, Jinan 250012, Shandong, China
  • Received:2015-02-03 Online:2015-11-10 Published:2015-11-10

PDF (PC)

203

Abstract: Objective To compare the efficacy and safety of dabigatran etexilate with warfarin for thromboembolism prevention in patients with nonvalvular atrial fibrillation. Methods A total of 166 patients with nonvalvular atrial fibrillation were identified as dabigatran etexilate group (110 mg, twice daily) and warfarin group (target international normalized ratio, 2.0~3.0). The efficacy and safety of the two drugs were compared in regard to stroke or systemic embolism and major bleeding outcomes during a follow-up of 6 months. Results In the thromboembolism events, there was no significant difference between dabigatran etexilate group and warfarin group (0.0% vs 1.2%, P>0.05). The rate of bleeding was 4.82% in the dabigatran etexilate group, as compared with 6.02% in the warfarin group (P>0.05). Conclusion There are similar thromboembolism and bleeding rates in patients with nonvalvular atrial fibrillation between dabigatran etexilate and warfarin.

Key words: Dabigatran etexilate, Thromboembolism, Nonvalvular atrial filbrillation, Warfarin

CLC Number: 

  • R541.7
[1] Olsson LG, Swedberg K, Lappas G, et al. Trends in stroke incidence after hospitalization for atrial fibrillation in Sweden 1987 to 2006[J]. Int J Cardiol, 2013, 167(3): 733-738.
[2] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study[J]. Stroke, 1991, 22(8): 983-988.
[3] Flegel KM, Shipleya MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation[J]. Lancet, 1987, 1(8532): 526-529.
[4] Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study[J]. Stroke, 2005, 36(6): 1115-1119.
[5] Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study[J]. Stroke, 1996, 27(10): 1760-1764.
[6] Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study[J]. Heart, 2001, 86(5): 516-521.
[7] Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study[J]. JAMA, 2001, 285(18): 2370-2375.
[8] Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study[J]. Eur Heart J, 2006, 27(8): 949-953.
[9] 周自强, 胡大一, 陈捷, 等. 中国心房颤动现状的流行病学研究[J]. 中华内科杂志, 2004, 43: 491-494.
[10] Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China[J]. J Am Coll Cardiol, 2008, 52(10): 865-868.
[11] Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate[J]. Clin Pharmacokinet, 2008, 47(5): 285-295.
[12] Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open label, parallel-group, single-centre study[J]. Clin Pharmacokinet, 2010, 49(4): 259-268.
[13] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12): 1139-1151.
[14] Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation[J]. Stroke, 2013, 44(7): 1891-1896.
[15] Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with Aatrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial[J]. Circulation, 2011, 123(21): 2363-2372.
[16] Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation an analysis of patients undergoing cardioversion[J]. Circulation, 2011, 123(2): 131-136.
[17] Providencia R, Albenque JP, Combes S, et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis[J]. Heart, 2014, 100(4): 324-335.
[18] Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study[J]. J Am Coll Cardiol, 2013, 6(22): 2264-2273.
[19] Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves[J]. N Engl J Med, 2013, 369(13): 1206-1214.
[20] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol, 2014, 64(21): 1-76.
[1] LIANG Lining, ZHONG Xia, JI Xianfei, HU Haoran, ZHU Fangfang, CHEN Jibin,CHEN Qianqian, SHANG Deya. Protective effects of post-conditioning with nicorandil on myocardial, cerebral and renal ischemia-reperfusion injury following cardiac arrest in swine [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 46-51.
[2] WEI Jinqiu, ZHANG Yujiao, LI Zhan, WANG Ximin, CHEN Linlin, DU Juanjuan, ZHANG Yong, XIE Xinxing, HOU Yinglong. Effects of GCH1 on atrial autonomic nerve remodeling by regulating tetrahydrobiopterin in A-TP canines [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 8-12.
[3] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(2): 95-96.
[4] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(11): 95-96.
[5] LI Man, ZHONG Jingquan, YUE Xin, ZHU Qing, ZHENG Zhaotong, RONG Bing, YI Shaolei, XIE Fei, ZHANG Yun. Effect of different circumferential pulmonary vein ablation endpoints on prognosis of atrial fibrillation patients:bidirectional block between pulmonary veins and left atrium [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(3): 62-68.
[6] LI Cong, WANG Jianchun, ZHAO Yong, ZOU Chengwei, SUN Hui, ZHANG Qing. Association between calcineurin-nuclear factor of activated T cell pathway and atrial fibrillation in patients with valvular heart disease [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(8): 47-51.
[7] ZHENG Shao-hua1, ZHANG Yu-jiao1, LI Zhi-yuan2, HOU Xu-juan3, WANG Xi-min1, DUAN Wen-chang4, HOU Ying-long1. Autonomic neural remodeling of pulmonary vein-left atrium junction in a prolonged right atrial pacing canine model [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(12): 7-10.
[8] LIU Wen-ting, LIU Tong-bao. Differential procedure of narrow QRS complex tachycardia based on lead V1 and avL in electrocardiograms [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(9): 67-71.
[9] FU Kai-li1, ZHANG Xue-yi2, ZHU Meng3, WANG Zhi-hao1, WANG Hua1, ZHONG Ming1, ZHANG Yun1, ZHANG Wei1. Evaluation of stroke risks in patients with atrial fibrillation due to different pathogenesis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(06): 61-63.
[10] LIU Xiao-jun, ZHONG Jing-quan, YI Shao-lei, XU Zhen-xing, LI Man, ZHANG Yun. Electrocardiographic characteristics and radiofrequency catheter ablation of idiopathic ventricular tachycardias or premature ventricular contractions originating from the two non-classical sites [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(4): 42-46.
[11] SUN Xue-lin1,2， BU Pei-li1， LIU Jun-ni1， CAO Guang-qing3， LI Li4， YU Qiong4. Relationship between SIRT1 expression in atrial tissue and
atrial fibrosis in patients with atrial fibrillation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 68-72.
[12] HU Ke， CHEN Liang-hua， SONG Shang-ming， LIU Tong-bao. Clinical application of aortography and local electrophysiological characteristics at the aortic sinus cusps [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(7): 92-96.
[13] WANG Wei-jie, ZHANG Yu-jiao, GAO Mei, WANG Jiang-rong, HOU Ying-long. Effect of rosuvastatin on the structural remodeling of
atrium in rabbits with myocardial infarction [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(4): 29-32.
[14] WANG Bo-song, ZHONG Jing-quan, LI Jing-sha, ZENG Qi-xian, LIU Hong-zhen, SU Guo-ying, LIU Dong-lin， ZHANG Yun. Comparison of effects of continuous and one-shock defibrillations on a  canine model of prolonged ventricular fibrillation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(3): 37-.
[15] WANG Bo-song, ZHONG Jing-quan, LI Jing-sha, ZENG Qi-xian, LIU Hong-zhen, SU Guo-ying, LIU Dong-lin， ZHANG Yun. Comparison of effects of continuous and one-shock defibrillations on a  canine model of prolonged ventricular fibrillation [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(3): 37-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd